阿巴西普治疗系统性硬化症的安全性与有效性:EUSTAR 经验
结果显示 28 个月治疗期间报告 16 例不良事件,多数发生于起始治疗后前 3 个月;治疗 12 个月后压痛关节数和肿胀关节数较基线下降,HAQ-DI 在 3 和 6 个月、晨僵在 6 和 12 个月改善,改良 Rodnan 皮肤评分下降,肺和胃肠道受累无变化。
要点
- 阿巴西普在系统性硬化症常规治疗中显示良好安全性,不良事件多集中于起始治疗后前 3 个月。
- 治疗 12 个月后压痛和肿胀关节数较基线下降,HAQ-DI 和晨僵在相应时间点改善。
- 改良 Rodnan 皮肤评分下降,但肺和胃肠道受累未见变化。
核心结论
- 阿巴西普在系统性硬化症患者中显示良好安全性,并似乎对关节受累及相关残疾有一定有效性。
主要发现
- 阿巴西普主要使用指征为关节受累(59%),其次为肌炎(26%)。
- 28 个月阿巴西普治疗期间报告 16 例不良事件,其中 5 例需住院,多数发生于起始治疗后前 3 个月。
- 治疗 12 个月后压痛关节数(p<0.03)和肿胀关节数(p<0.02)较基线下降。
- HAQ-DI 在 3 和 6 个月改善(p<0.05),晨僵在 6 和 12 个月改善(p<0.03),改良 Rodnan 皮肤评分下降(p<0.05),肺和胃肠道受累无变化。
临床怎么用
- 在系统性硬化症常规治疗中,阿巴西普可用于以关节受累为主要表现的患者,并需关注起始治疗后前 3 个月的不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the safety and effectiveness of abatacept (ABA) given in routine care to patients with systemic sclerosis (SSc). METHODS: Retrospective multicenter observational study that enrolled patients with SSc treated with ABA. We collected epidemiological data and clinical outcomes. First, we analyzed the frequency of adverse effects. Secondly, we compared the evolution of different organ manifestations during ABA treatment. We collected data from 6 months before start of therapy to the last follow-up the following parameters: modified Rodnan Skin Score (mRSS), joints, lung and gastrointestinal involvement, concomitant medications, and laboratory tests. RESULTS: Data on twenty-seven patients with SSc were collected (93% females; 67% limited SSc). Rheumatoid arthritis was the most frequent concomitant autoimmune disease. ILD was present in 15 patients. Anti-Scl 70 antibodies were present in 13 patients and rheumatoid factor and ACPA antibodies were present in eight and seven patients respectively. The main indication to use abatacept was joint involvement (59%) followed by myositis (26%). A total of 16 adverse effects were reported in 28 months of abatacept treatment including five that required hospitalization. Most of them occurred in the first 3 months after starting abatacept. After 12 months, the number of tender and swollen joints decreased compared to baseline (p<0.03 and p<0.02 respectively). Moreover, a beneficial effect of abatacept on HAQ-DI at 3 and 6 months (p<0.05) and on morning stiffness at 6 and 12 months (p<0.03) was observed. We also observed a decrease in the modified Rodnan skin score (p<0.05). No changes in lung or gastrointestinal involvement were found. CONCLUSIONS: ABA demonstrated a good safety profile and seems to have some effectiveness on joint involvement and related disability in SSc patients treated in routine care.
引用
- Castellví I, Elhai M, Bruni C, et al. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Semin Arthritis Rheum. 2020. PMID: 32165035. doi:10.1016/j.semarthrit.2019.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。